ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9776	Companies
195668	Keywords
126689	Articles
104037	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 01/21/2026 at 18:05, 9 days ago

FDA Grants Orphan Drug Status to OSE Immunotherapeutics' Pegrizeprument

OSE Immunotherapeutics FDA Orphan Drug Pegrizeprument Organ Transplantation Veloxis Pharmaceuticals
PRESS RELEASE

published on 01/21/2026 at 18:00, 9 days ago

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics acknowledges FDA Orphan Drug Designation granted to pegrizeprument (VEL-101) for organ rejection prevention in liver transplant patients. Veloxis Pharmaceuticals to develop and commercialize the product globally

FDA Orphan Drug Designation OSE Immunotherapeutics Pegrizeprument VEL-101
BRIEF

published on 12/09/2025 at 07:35, 1 month 21 days ago

OSE Immunotherapeutics Announces Strategic Plan for 2026–2028

Strategic Plan Financial Strategy Scientific Leadership Tedopi Trial Lusvertikimab Development
BRIEF

published on 12/09/2025 at 07:35, 1 month 21 days ago

OSE Immunotherapeutics' new strategic plan for 2026-2028

Strategic Plan Funding OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
PRESS RELEASE

published on 12/09/2025 at 07:30, 1 month 21 days ago

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership

Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
BRIEF

published on 10/15/2025 at 19:05, 3 months 14 days ago

OSE Immunotherapeutics Reports 2025 First Half Financial Results

Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE

published on 10/15/2025 at 19:00, 3 months 14 days ago

OSE Immunotherapeutics Reports First Half 2025 Financial Results
OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7%

Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
BRIEF

published on 10/09/2025 at 16:02, 3 months 21 days ago

OSE Immunotherapeutics: End of a concerted action between shareholders

Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
BRIEF

published on 09/30/2025 at 19:35, 3 months 29 days ago

OSE Immunotherapeutics: Reorganization of the Board of Directors

Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
PRESS RELEASE

published on 09/30/2025 at 19:30, 3 months 29 days ago

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
OSE Immunotherapeutics renews Board of Directors and elects Dr. Markus Cappel as Chairman. Shareholders vote on key appointments

Board Of Directors Shareholders General Meeting OSE Immunotherapeutics Dr. Markus Cappel

1 2 ... 5

Accesswire

Published on 01/30/2026 at 14:00, 4 hours 18 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 9 hours 43 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 10 hours 18 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 16 hours 3 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 18 hours 18 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 17:55, 23 minutes ago

Wellington College International to Open First African School in Alaro City, Lagos in 2027
Published on 01/30/2026 at 17:29, 49 minutes ago

EQS-Adhoc: The Payments Group Holding GmbH & Co. KGaA: The Payments Group Holding – Successful issuance of convertible bond
Published on 01/30/2026 at 17:09, 1 hour 9 minutes ago

Halfords Group PLC: Total Voting Rights
Published on 01/30/2026 at 16:54, 1 hour 23 minutes ago

Holding(s) in Company
Published on 01/30/2026 at 16:46, 1 hour 32 minutes ago

Custodian Property Income REIT plc: Investor Presentation via Investor Meet Company

Les Echos

Published on 01/30/2026 at 17:45, 33 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 10 hours 18 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE